NCT05855538Completed
Clinical Cohorts for Validation of New Digital Biomarkers
Machine Learning and Artificial Intelligence for Early Detection of Stroke and Atrial Fibrillation. Clinical Cohorts for Validation of New Digital Biomarkers
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
The MAESTRIA study is an international, multi-centre, non-interventional, observational registry. The main goal is to enrol a representative group of European patients diagnosed with Atrial Fibrillation (AF) to analyse clinical and relevant parameters (digitalised ECG, echocardiograms, cardiac CTs, MRIs and blood biomarkers) that could be used during clinical practise for the diagnosis of atrial cardiomyopathy. The AF patients will be distributed in 3 groups according to the different manifestation of AF: paroxysmal, persistent and permanent AF.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 515 (actual)
- First submitted
- 20 Mar 2023
- Start date
- 2 Mar 2023
- Primary completion date
- 24 Jul 2026
- Lead sponsor
- Atrial Fibrillation Network
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT05855538
What you commit to
- Study type: Observational
- Participants enrolled: 515
- From 2 Mar 2023 to the primary completion date, 24 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any disease that limits life expectancy to less than 1 year.
- Any medical or psychiatric condition which, in the investigator´s opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
Other
- All persons unable to provide informed consent.
- All persons exempt from participation in a study or trial by law.
Who the study is looking for
- Patients with paroxysmal AF, persistent AF or permanent AF.
- Patients (or legally acceptable representative if applicable to country specific regulations) provide written informed consent to participate in the study. The patient has the option to give separate consent to donate extra volume of blood during the routine blood collection, that can be used for biomedical research.
- Patient is at least 18 years old.
- Patient must own a smartphone with Apple iOS version 14.5 (or higher) or with Android version 8.0 (or higher).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St Vincenz Hospital Coordinator of this site? Confirm its status | Paderborn | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.